## Public Health <br> England

## Action notes

Title of meeting: Date:
Time:
Venue:
Dial in details:

NHS Health Check Expert Scientific and Clinical Advisory Panel Tuesday 1 November 2016
10:00-12:00
Board Room, Wellington House,133 - 155 Waterloo road, SE1 8UG

## Attendees:

| Chair | John Newton, Chief Knowledge Officer, PHE <br> Jamie Waterall, national lead and deputy chief nurse, CVD <br> prevention team, PHE <br> Lynda Seery, Public Health Specialist, Newcastle City Council <br> Charles Alessi, Senior Advisor, PHE <br> Jonathan Valabhji, National Clinical Director for Obesity and Diabetes, NHS England <br> Felix Greaves, Deputy Director, Science and strategic information <br> Matt Kearney, National Clinical Director for Prevention, NHS England <br> Huon Gray, National Clinical Director for Heart Disease, NHS <br> England <br> Nick Wareham, Director of the MRC Epidemiology Unit and co- <br> Director of the Institute of Metabolic Science <br> Judith Richardson on behalf of Mark Baker, Centre for Clinical <br> Practice Director - NICE <br> Richard Fluck, Chair of the Internal Medicine Programme of Care board. <br> Gillian Fiumicelli, Head of vascular disease prevention, London <br> Borough of Bromley <br> Martin Vernon, National Clinical Director for Older People, NHS England. <br> Alistair Burns, National Clinical Director for Dementia, NHS England |
| :---: | :---: |
| Telephone | Zafar Iqbal, Deputy Director of Public Health, Stoke on Trent |
| Guest | James Woodcock, Programme Lead: Public Health Modelling, Cambridge University |
| Guest | Oliver Mytton, Honorary Specialty Registrar/PhD Candidate, Cambridge University |
| Guest/telephone | Catherine Lagord, Analyst, CVD prevention team PHE |
| Guest | Allison Streetly, Deputy Director Health Care Public Health, PHE |
| Guest <br> Guest <br> Secretariat | Nerissa Santimano, Population health services manager, PHE Slade Carter, Deputy national lead, CVD prevention team, PHE Katherine Thompson, Deputy national lead, CVD prevention team |

## PHE

Secretariat Hannah Rees, Senior support manager, CVD prevention team, PHE

| Apologies | Ash Soni, Vice Chair, English Pharmacy Board |
| :--- | :--- |
| Annmarie Connolly, Director of Health Equity and Impact, PHE |  |
| Theresa Marteau, Director of the Behaviour and Health Research |  |
| Unit, University of Cambridge |  |
| Anne Mackie, Director of programmes, UK NSC |  |
| John Deanfield, Director of National Centre for Cardiovascular |  |
| Prevention and Outcomes |  |
| Kevin Fenton, Director of Health and Wellbeing, PHE |  |
| David Wood, Professor of Cardiovascular medicine, Imperial College |  |
| London |  |
| Peter Kelly, Centre director North East, PHE |  |
| Anthony Rudd, National Clinical Director for Stroke, NHS England |  |


| Timings | Item Description | Lead |
| :--- | :--- | :--- |
| $10: 00-$ | 1. Welcome and apologies <br> $10: 05$ <br> As shown on page 1 and 2. | JN |
| $10: 05-$ | 2. Actions from the last meeting <br> Action 16 - KT to circulate the call for NHS Health Check <br> conference abstracts to members. <br> Complete. <br> Action 17 - KT and MK to have a follow up discussion with <br> the Liverpool university researchers to explore potential <br> future modelling scenarios. <br> Complete. <br> Action 18 - SC to speak to Gyles Glover about his approach <br> to ethics for the national data extraction that he completed. <br> Complete. <br> Action 19 - SC to speak with Robert Kyffin to confirm <br> whether or not type 2 exclusions can be included in the <br> national data extraction and to explore potential sublicensing <br> opportunities. <br> In discussion. <br> Action 20 - As the national data extraction work progresses, <br> SC to consider putting together an academic advisory group <br> as a sub-group of ESCAP. <br> Complete. SC is bringing together the basis for an advisory | JW |


| Timings | $\quad$ Ltem Description | Lead |
| :--- | :--- | :--- |
|  | group. <br> Action 21 - KT to revise the ToR to include the proposed <br> changes on membership and CARE. <br> Complete. <br> Action 22 - HR to ask LINF to identify another LA <br> commissioner to attend the ESCAP group. <br> Complete. <br> Action 23 - MK to identify a primary care expert to join the <br> group. <br> The group agreed that Dr Ruth Chambers would be invited to <br> join the meeting. <br> Action 24 - KT to ask Ash Soni to delegate attendance. <br> Complete. <br> Action 25 - KT to explore how community pharmacy <br> expertise could be strengthened on the group. <br> KT has been liaising with PHE/DH pharmacy lead to identify <br> potential candidates. <br> Action 26 - SR to identify a digital expert to join the group |  |
| In progress. <br> Action 27 - KT to amend the ToR to reflect that ESCAP will <br> also provide advice, as requested, on the broader CVD <br> agenda. <br> Complete. <br> The group agreed that it would be helpful to have Michael <br> Soljack and John Robson as advisors to the committee. |  |  |
| $10: 15-$ | 3. Programme update <br> JN confirmed that he and KT had submitted a 300 word <br> version of the electronic right to reply to the Canadian <br> Medical Association Journal. The response will be published <br> in the December edition of the journal. <br> Action 28- KT to circulate the shortened CMAJ right to reply <br> text to the group. <br> Action 29 - KT to recirculate PHEs publication: Action on <br> Cardiovascular disease: getting serious about prevention to <br> members. <br> Action 30 - KT to explore the possibility of an NHS Health <br> Check supplement in the journal of public health using the <br> submitted conference abstracts. |  |


| Timings | $\quad$ Item Description | Lead |
| :--- | :--- | :--- |
|  | Action 31 - ZI to share the contact details of the JPH editor <br> with KT. <br> Action 32 - KT to circulate the CVD conference registration <br> link when it goes live. <br> Action 33 - KT to circulate the link to the heart age BMJ <br> paper. <br> Concern regarding reduced local authority delivery activity <br> was raised. JW confirmed that reductions in offers and the <br> number of people having a check was discussed at the last <br> National Advisory Committee meeting and that a briefing has <br> recently gone up to the Parliamentary Secretary for <br> Community Health and Care highlighting the issue. PHE is <br> currently in conversation with LGA and ADPH about the <br> impact of the public health grant reductions and local budget <br> pressures on the implementation of the programme. PHE is <br> bringing together a range of actions seeking to address this. <br> KT confirmed that the NHS Health Check evidence synthesis <br> work has been awarded to Cambridge University. The team <br> is headed up by Prof. Jonathan Mant and also draws on the <br> expertise of RAND. The report will be ready for the <br> conference on the 9 February. |  |
| $10.30-$ | 4. Results from a Microsimulation Model of the Health <br> Checks Programme. | JWo/OM |
| 11.00 | The "no health checks" scenario is based on standard care <br> so people are getting regular reviews/management in primary <br> care. <br> The group agreed that they were not clear on what the main <br> output of QALY days gained per capita meant and that there <br> was a danger of misinterpretation. It was agreed that the way <br> the outputs of the model were expressed and communicated <br> would be revisited and other outcomes explored i.e. <br> premature deaths or disease avoided and that the <br> researchers would provide like for like comparators to assist <br> with interpreting the QALY messaging. <br> There was also discussion that recent research had <br> demonstrated statin prescribing rates of at least 40\% in those <br> at high risk. As the counterfactual level used in the model <br> was only 36\%, members agreed that it would be valuable to <br> understand what the impact might be if a more ambitious <br> aspirational counterfactual for statin prescribing levels was <br> adopted. <br> Action 34 - Matt Kearney to share an evidence based figure <br> for levels of statin prescribing with James Woodcock. This is |  |


| Timings | $\quad$ Item Description | Lead |
| :--- | :--- | :--- |
| $11.00-$ | intended to inform the inclusion of a higher counterfactual <br> figure in the microsimulation model. |  |
| 11.20 | Members agreed that the NHS HC provides an opportunity to <br> encourage cascade testing as part of the cholesterol <br> information in the best practice guidance. | AS |
|  | It was suggested that the CVD risk register component of the <br> NHS Health Check pathway could be strengthened to better <br> reflect the management of cholesterol. There was also some <br> discussion of the need to strengthen existing communications <br> to raise the profile of cholesterol. | Action 35 - NS to input in to the refresh of the NHS Health <br> Check best practice guidance. <br> JW confirmed that there will be a round table discussion <br> about statin prescribing with the deputy chief medical officer <br> on the 14 November. |
| $11.20-$ | 6. Content review process <br> Members discussed the findings from the public consultation <br> on the diabetes filter. The group agreed that the <br> recommendation will remain unchanged. <br> There was some discussion on whether NICE would be able <br> to make a recommendation on "at risk" thresholds as part of <br> the review of the diabetes prevention guidance. However, the <br> group was advised that this is likely to be beyond the remit of <br> NICE's work. <br> Action 36 - John Newton to write to Mark Baker asking NICE <br> to consider defining high risk as part of their update to their <br> guidelines. | KT |
| $11.30-$ | 7. Dementia pilots <br> PHE, Alzheimer's Research UK and Alzheimer's society, in <br> partnership with three local authorities have now launched <br> pilots testing the delivery of dementia risk reduction <br> messages to anyone having an NHS Health Check. <br> Although it is early days the take home messages so far is <br> that people delivering check find it hard to talk about <br> dementia in the younger age ranges. Despite this the patients <br> seem to welcome the opportunity to have a conversation <br> about dementia. <br> Action 37 - CA to provide an update on the pilots at a future | CA |
| 11.40 |  |  |


| Timings | Item Description | Lead |
| :--- | :--- | :--- |
|  | ESCAP meeting. <br> The question of whether it is known that preventing CVD <br> events reduces incidence of dementia was raised. The <br> evidence on this is currently unclear. | SC |
| $11.40-$ | 8. National data extraction [standing item] <br> SC confirmed that the specification for the data extraction is <br> now complete and that the direction needed from the <br> Secretary of State for Health to allow NHS Digital to perform <br> the extraction is in draft. A workshop on data management <br> i.e. security and storage was delivered and is informing PHEs <br> actions in preparing to receive the data. A further workshop is <br> planned for December and an academic advisory group is <br> being established. | All |
| $11: 50-$ | 9. AOB <br> Martin Vernon raised the question of how we keep the over <br> 75 population healthy and well. The group agreed that it <br> could be an interesting topic for future conversation and it <br> may be valuable to consider whether different (older) age <br> groups should also be invited for a check as part of the <br> content review process. |  |
| $12: 00$ | ( |  |

